univers coverag
calendar event
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
great last year lower mp stock fairli
 methodolog dcf sop analysi discount rate termin growth
bottom line downgrad market perform outperform base view
compani clinic stage pipelin fairli valu visibl addit near-
term sourc upsid limit bullish base thesi would
abl overcom technic challeng regard lead gene therapi product lentiglobin transfusion-
depend beta-thalassemia tdt sever sickl cell diseas scd compani car-t
product underappreci investor link share appreci
vs nbi sinc initi coverag februari manag execut
well term advanc pipelin today downgrad share market perform
think market cap pipelin fairli valu look execut
year visibl addit value-cr catalyst alreadi reflect stock
limit view investor understand enthus recent uptick activ
sector said trade ev revenu forecast think share
includ signific premium think may ultim acquir difficult
predict acquisit happen near term updat pt
includ acquisit premium lower wacc assumpt
look execut year
model account high probability-of-success clinic stage pipelin
stock trade similar rel absolut valuat juno kite acquisit price
revenu million
bottom line expect sever flu steeper season hdhp conserv guidanc
consensu potenti improv ebitda achiev tax reform offer upsid
much profit less lever name qualiti acut pick
buy valu special situat pick activ restructur expect
compani offer direct color guidanc tax reform quarter import
catalyst particular absent recent competitor confer typic
offer formal guidanc
hurrican drove earn miss conserv guidanc estim
built hurrican impact baselin offer better earn achiev
tax reform offer ep upsid higher earn less lever name even lead
 even dividend
season uptick exhaust copay deduct could stabil pressur
weak volum ed surgeri ip op mix shift ambulatori set
strong flu season could help volum
survey result indic modest yoy acceler util across care deliveri set
ip inpati op outpati ambulatori surgeri center ed believ also
partli due higher flu part steeper season hdhp
payor mix pressur could persist acut mix shift lower price govern busi
bad debt could improv sequenti member reach copay deduct
side swb salari wage benefit oper expens expect improv
sequenti due absenc hurrican
acut compani focus strategi off-set secular pressur volum
acquir divest asset meet debt commit
less posit bh valu name given lo length stay stabil acut still
look solid tax reform offer upsid pois reach regulatori settlement state
feder agenc expect next month
remain highli lever progress made reduc leverag asset
 methodolog dcf analysi discount rate tg rate
bottom line today publish first seri piec ttr amyloidosi market
initi focu impact renegoti agreement sni op market
opportun present addit ttr indic full control ttr franchis increas
bullish abil expand size pie patisiran ttrsc sq especi
wild-typ ttr diseas howev enthusiasm soften one confound factor second
gen medicin look much attract even price pariti much less profit product
even expand ttr market opportun cannib patisiran view inevit
within consid revenu potenti addit ttr indic market expans via
sq balanc clinical/commerci risk variou patisiran cannib scenario remain mp
increas pt
first multipl note ttr seri explor multipl key commerci question
potenti indic outlin sq wild-typ ttr view interest
area market expans
new price target base multipl scenario blend two differ
revenu million ep
bottom line convers health actuari medicar advantag specialist point
bottom advanc rate notic mid point larg
consist bullish top view dc health tax polici analyst first
year new republican see rate notic key catalyst group
overal particular op op wcg op investor view rate polici
seri attract tax polici chang drive irrevers privat current one third
american senior elect like issu soft guidanc plan
use tailwind year hipf moratorium like even tax reform toward membership gain
rather margin expans though remain accret given privat new
ff senior alreadi attract oper profit pmpi growth percentag
medicar truste report key tailwind off-set headwind rang flat
ff normal rate risk adjust chang unlik meaning
impact though rebas growth rate counti could potenti wild card light macra
spoke two medacorp health actuari specialist health polici specialist gain
direct insight rate notic polici environ
schedul releas advanc rate notic medicar advantag jan
notic particularli import catalyst year given first full year new trump
republican super major
tax reform polici recent legisl year hipf delay like figur soft guidanc
use rate tax tailwind drive membership gain accret medicar advantag
given one third live privat manag enjoy strong oper profit per member
top polici view bottom actuari view converg rate rang
rate impact rate despit propos prevent cross
walk membership low high rate plan
similarli risk code intens adjust larg flat modest posit impact new
risk adjust methodolog issu dec offset annual bp headwind
outlook sale growth momentum pois continu new
 methodolog ep estim
bottom line today share trade higher -- justifi -- compani deliv anoth
solid quarter improv fundament issu bullish importantli think achiev
guidanc suggest strong sale momentum continu us encourag
part today print growth acceler driven sever key recent
product launch includ suit mri safe high power devic freestyl libr turnaround
intern nutrit seem improv market condit china eas
compar alr acquisit complet integr underway nit quarter --
-- guidanc suggest modest margin contract vs optic certainli
posit note driver margin contract includ alr gross margin dilut
pension-rel incom report incom oper incom line due
account standard chang manag expect reinvest larg portion upsid
higher sale lower tax rate busi fund futur growth us much
execut stori compani integr two recent major acquisit stj alr
drive new product cycl medic devic busi steadi turnaround
nutrit busi quarter perform seem posit datapoint support
view success execut valuat rel now-high expect
keep us sidelin acknowledg fundament seem improv
reiter mp pt
revenu mm ep includ stock compens expens exclud amort
 methodolog blend dcf valuat thru dr
tgr sotp analysi
bottom line follow strong quarter above-consensu guidanc top
expect see notabl currenc tailwind increas forecast intern
innov medicin alcon sale rel meaning data readout year
except possibl interim look entresto paragon trial larg execut
year result chang model price target repres blend
dcf valuat sotp analysi reiter mp
bottom line symphoni health sale avail bloomberg show overal immuno-
oncolog io sale among compani rel flat m/m decemb factor one fewer
sell day decemb vs novemb daili sale decemb
novemb overal market share dynam larg unchang op opdivo nivolumab
vs prior month share i/o market yervoy ipilimumab
share us io market declin point novemb share
mp keytruda pembrolizumab increas touch novemb
market share rhhbi tecentriq atezolizumab mp bavencio avelumab
rel flat m/m azn mp imfinzi durvalumab share increas
neglig share market octob imflinzi market share gain could earli
sign enthusiasm medacorp oncolog specialist express recent publish lung cancer
appoint rhonda robb major win
bottom line morn announc rhonda robb appoint chief oper
offic depart prior posit head mp heart valv busi us major win
robb signific oper experi help build valv busi
last year signific new product launch experi
valv busi deliv technolog iter everi year signific experi
street time robb also previous work ceo scott ward
head cardiovascular busi seem bring robb result
activ search consid prior kevin kenni departur announc decemb
due person reason regardless robb arriv us valid technolog
strategi also signal potenti improv fundament go forward given robb signific
oper experi expect share react posit announc would
recommend buy even strength
amazon entri like slow sell-off overdon
rx jan call insight like tortois less like hare
insight amzn strategi approach lab suppli product
potenti amazon impact gener compani takeaway
investor day highlight potenti disrupt landscap pt
 methodolog dcf discount rate termin growth
rapid enrol across orion trial support optim inclisiran
sophia ph pass interim futil analysi remov overhang data
 methodolog dcf base upon wacc termin growth rate
pt
 methodolog ep
end-market fundament outlook solid upcom
present updat plu everolimu ph ib data rcc initi ph ib
plu cabozantinib data rcc asco-gu
set investor expect ahead asco-gu manag indic
cabozantinib combin data base initi cohort dozen patient
activ dose includ safeti earli efficaci data focu
manag view benchmark beat studi object respons
rate achiev cabozantinib meteor studi note earli
discuss progression-fre surviv asco-gu
regard everolimu combin data manag indic updat
simpli matur previous present data
believ investor expect program overal across variou
combin indic pursu low current stock level stock
follow initi data plu opdivo ph studi
continu view current valuat attract entri point long-term
tezacaftor/ivacaftorfor homozyg offer improv toler profil
orkambi potenti approv offer underappreci volum revenu gain
find vertex tez/iva potenti approv low-risk meaning catalyst
vertex sinc combin improv toler profil increas penetr
orkambi exist indic enabl re-treat prior discontinu
management describ tezacaftor/ivacaftor potenti approv greatest near-term driver
top-lin growth us launch
investor could also benefit confirm develop timelin vertex novel
tripl combin therapi begin pivot trial could result
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
cdtx rezafungin iv phase ii data candidemia system candida
phase ii strive data rezafungin iv expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
analysi commerci opportun confer augment suggest success
worth per share
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi asah patient pivot event edg share set in/around
compani conduct interim analysi see binari event
upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom httrx result import potenti roch
opt-in right
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
bold ph i/ii xlmtm crigler-najjar syndrom data
audent expect announc updat phase i/ii aspiro data x-link
myotubular myopathy/xlmtm well preliminari phase i/ii valen data crigler-
najjar syndrom
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
state union address
like advanc rate notic medicar advantag
fda adcom joint meet anesthet analges drug product drug
safeti risk manag
fda adcom anesthet analges drug product
pdufa peg-pal phenylketonuria tezacaftor/ivacaftor cystic
propos hous appropri committe deadlin fund feder government
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
fda adcom gastrointestin drug panel snda xeljanz ulcer
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
pdufa akao plazomycin complic urinari tract infect bloodstream
societi thorac surgeon
societi matern fetal medicin pregnanc meet
american colleg radiat oncolog
societi laboratori autom screen
associ access medicin
advanc genom biolog technolog
european crohn coliti organis
advanc technolog treatment diabet
multidisciplinari head neck cancer symposium
american academi dermatolog
bmt tandem meet american societi blood marrow transplant
asbmt center intern blood marrow transplant research cibmtr
societi critic medicin sccm
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
medic suppli devic individu co preview cardio large-cap diversifi
 first apprais tax offer small benefit
 state larg cap biotech sfo steadi goe
 preview tax reform guidanc imp catalyst aet
shade grey
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
 aet seek creat new low-cost community-bas model
-- flash /aet may closer deal combin would creat
manag -- flash cvs-aet like dec per share mix
 equiti question gupt ana
aet -- flash anoth rais pbm qs
 volum start show improv respond aggress
 outperform larsen david
manag aet offens defens consum deal
 aet bring comprehens member
-- flash dementia psychosi btd po surpris basket high risk/
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 lp hic panel controversi focu ahead data
 roll new ttr model updat spinraza pipelin pt market
 synergi specialti purchas aggress medic
hcit distribut outlook increasingli competit suppli chain
shift vbc
hcit distribut amazon estim matter
hcit distribut wholesal licens may start hub spoke
hcit distribut enter brick mortar space pbm deal could
hcit distribut like take modest size step pharmaci
manag entri drug distribut chain
healthcar distribut suppli chain preview price volum trend
manag -- flash marriag aet jilt altar toward
optum wanna-b
-- flash comment stir lab suppli busi back
controversi focu ahead drug launch
futur major invest theme backdrop clinic risk
-- flash fourier result chang standard cv patient
 fourier lift statin throne plausibl like
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma leerink confer offer first mani face offswil
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic cgm libr impact market uncertain still oversold
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 american academi neurolog planner
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
 outlook smid biotech theme rnai/antisens id
gwph qtr recap dinner physician bullish uptak ahead
gwph/aan presentation/kol event -- epidiolex profil continu look favorable/
 build solid foundat xlh data could posit ahead
gwph lower pt better data setup still solid
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
scmp d/g mp acquisit bullish data pt
-- flash partner drug advanc phase outperform
 celg defend celgen could
self-help stori
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 analyst event best idea
outperform
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma us biopharma product updat lli premium us
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight breast cancer kol discuss
biopharma highlight lung cancer kol discuss
biopharma highlight asthma/copd kol discuss
biopharma highlight immuno-oncolog kol discuss
biopharma highlight myeloma kol discuss
window rival
biopharma highlight heart failur kol discuss
 mix outlook physician survey regard intrarosa
 pbc survey suggest ocaliva safeti concern manag
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit azn
medic suppli devic survey suggest pickup procedure/
 physician survey support nerlynx opp ty breast cancer pt
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
